Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disease that is usually classified either ulcerative colitis (UC) or Crohn’s disease (CD). Though its exact pathogenesis remains unknown, there have been remarkable therapeutic advances with the widespread use of biologic therapies. Tumor necrosis factor-alpha (TNF) inhibitors, such as infliximab and adalimumab, can be used for UC and CD as a therapy to blunt the cytokine response produced by macrophages in the setting of endotoxins and oxidative stress [
1]. Nevertheless, by disrupting the host’s natural defense system, these immunosuppressive therapies increase the risk of opportunistic infections, which are associated with higher morbidity and mortality in this patient population. It is therefore paramount to recognize such infections and treat accordingly in a timely manner. In this case, we report an opportunistic infection of pulmonary
Histoplasmosis capsulatum in a patient receiving biologic therapy who developed systemic symptoms with new pulmonary nodules. …
